ATE312178T1 - Infektiöse pseudovirale papillomavirus partikel - Google Patents

Infektiöse pseudovirale papillomavirus partikel

Info

Publication number
ATE312178T1
ATE312178T1 AT97934126T AT97934126T ATE312178T1 AT E312178 T1 ATE312178 T1 AT E312178T1 AT 97934126 T AT97934126 T AT 97934126T AT 97934126 T AT97934126 T AT 97934126T AT E312178 T1 ATE312178 T1 AT E312178T1
Authority
AT
Austria
Prior art keywords
papillomavirus
gene
biological species
infectious
derived
Prior art date
Application number
AT97934126T
Other languages
English (en)
Inventor
Douglas R Lowy
John T Schiller
Richard B Roden
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE312178T1 publication Critical patent/ATE312178T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97934126T 1996-07-17 1997-07-14 Infektiöse pseudovirale papillomavirus partikel ATE312178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2210496P 1996-07-17 1996-07-17
PCT/US1997/012115 WO1998002548A2 (en) 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles

Publications (1)

Publication Number Publication Date
ATE312178T1 true ATE312178T1 (de) 2005-12-15

Family

ID=21807834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934126T ATE312178T1 (de) 1996-07-17 1997-07-14 Infektiöse pseudovirale papillomavirus partikel

Country Status (8)

Country Link
US (2) US6599739B1 (de)
EP (1) EP0922105B1 (de)
JP (1) JP2000515741A (de)
AT (1) ATE312178T1 (de)
AU (1) AU732125B2 (de)
CA (1) CA2257822A1 (de)
DE (1) DE69734829D1 (de)
WO (1) WO1998002548A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
WO2001002551A2 (en) * 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
GB0007231D0 (en) * 2000-03-24 2000-05-17 Chiron Spa Modified rna for gene delivery
US6841157B2 (en) * 2000-07-07 2005-01-11 Merck & Co., Inc. Production of chimeric human papillomavirus
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
ITVA20050021A1 (it) 2005-04-01 2006-10-02 Sergio Biucchi Dispositivi informatici off-line per il sistema delle transazioni valutarie autogestite
WO2007064971A2 (en) * 2005-12-01 2007-06-07 The Government Of The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Infectious papovavirus particle comprising a cytocidal gene and methods of use thereof
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
EP2416798B1 (de) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like partikel (vlp) als breitbandimpfstoffe gegen humanes papillomavirus (hpv)
ES2845212T3 (es) 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EA023897B1 (ru) * 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
EP4059521A1 (de) 2013-09-18 2022-09-21 Aura Biosciences, Inc. Virusähnliche partikelkonjugate zur diagnose und behandlung von tumoren
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
CN108473950A (zh) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 靶向癌症治疗
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
DE102016215500B4 (de) * 2016-08-18 2020-02-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sensorsystem zur Charakterisierung des Zustandes von in einem Kultivierungsgefäß enthaltenen Proben einer heterogenen Biomassestruktur
CA3059882A1 (en) 2017-04-12 2018-10-18 Aura Biosciences, Inc. Targeted combination therapy
EP3706783A1 (de) 2017-11-06 2020-09-16 The United States of America, as represented by the Secretary, Department of Health and Human Services Krebsbehandlung unter verwendung von bereits vorhandener mikrobieller immunität
CN116350803B (zh) * 2023-05-19 2023-11-24 健通(济南)生物科技有限公司 一种以乳头瘤病毒样颗粒为载体的mRNA递药系统及制备方法
WO2026055208A1 (en) 2024-09-04 2026-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particle conjugates comprising photoactivatable dye compounds and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5792931A (en) * 1994-08-12 1998-08-11 Pioneer Hi-Bred International, Inc. Fumonisin detoxification compositions and methods
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
FR2749323B1 (fr) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
CA2302545C (en) * 1997-09-05 2012-04-03 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)

Also Published As

Publication number Publication date
JP2000515741A (ja) 2000-11-28
WO1998002548A3 (en) 1998-03-05
US6599739B1 (en) 2003-07-29
EP0922105A2 (de) 1999-06-16
CA2257822A1 (en) 1998-01-22
DE69734829D1 (de) 2006-01-12
WO1998002548A2 (en) 1998-01-22
AU732125B2 (en) 2001-04-12
EP0922105B1 (de) 2005-12-07
AU3725697A (en) 1998-02-09
US20030207446A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
DE69734829D1 (de) Infektiöse pseudovirale papillomavirus partikel
GB2325003B (en) Rectroviral vectors
ATE270342T1 (de) Endosomolytisch wirksame partikel
DE60025037D1 (de) "functional genomics" unter verwendung von zink finger proteinen
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
DE69638196D1 (de) Rekombinantes sendai-virus
DE60020146D1 (de) Two-hybrid-Screeningverfahren unter Verwendung des bakteriellen Transcriptionsaktivators sigma-54
DK0862633T3 (da) VP-antigen af JC-virus
ATE288496T1 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
FR2755144B1 (fr) Fragments d'anticorps a chaine unique anti-p53 et utilisation
DE69739346D1 (de) Gereinigtes sr-p70 protein
EE05691B1 (et) Ekspressioonivektorid ja nende rakendused
AU8405798A (en) A swine hepatitis e virus and uses thereof
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
GB0216081D0 (en) Methods of making biological materials and uses thereof
DE69433787D1 (de) Von htlv-i und htlv-ii gp21 abgeleitete peptide zur diagnostischen verwendung
WO2000034335A3 (en) 'death domain' containing receptors
EP1083224A3 (de) Apoptin bindendes Protein
ATE352628T1 (de) Mosaikprotein und ligationsverfahren mit hilfe einer restriktionsendonuclease
ATE290093T1 (de) EXPRIMIERUNG EINES MODIFIZIERTEM ßFOAMY VIRUS ENVELOPE PROTEINß (HÜLLENPROTEIN)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties